Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Safety and Performance, and Dose, of OsteoAdapt DE in Localized Alveolar Ridge Augmentations

NCT: NCT07078331 · ACTIVE_NOT_RECRUITING

NCT IDNCT07078331
StatusACTIVE_NOT_RECRUITING
Start Date2025-07-17
Completion2026-12-31

Brief Summary

This study's objective is to evaluate OsteoAdapt DE's safety and performance in comparison to Xenograft particulate bone graft for alveolar ridge augmentation. Additionally, the study aims to optimize OsteoAdapt DE dosing for future studies by assessing two concentrations: a low dose (0.8 mg/cc) and a high dose (2.0 mg/cc).

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑